Navigation Links
Texas-based consortium announces groundbreaking vaccine research program
Date:2/24/2010

COLLEGE STATION, Texas - Leaders of the Texas Plant-Expressed Vaccine Consortium today announced a biotherapeutic manufacturing initiative designed to show proof of concept for a landmark new technology that could dramatically increase the nation's capability to produce vaccines for infectious diseases, including influenza.

Project GreenVax, which utilizes tobacco plants rather than the current egg-based vaccine technology, holds the promise of shortening vaccine production to a fraction of the current time, allowing rapid response to newly emerging viruses not possible with current technology. The majority of funding for the project is provided by the Defense Advanced Research Projects Agency (DARPA).

The Consortium, comprised of G-Con, LLC and The Texas A&M University System, designed Project GreenVax for a projected final scale capacity of 100 million doses per month. The flexibility of the plant-based system, combined with its low cost and ability to massively scale, may provide vaccine protection not only to citizens of the United States, but to many parts of the world that cannot currently afford vaccines.

The GreenVax Project will be headquartered on a secure, 21-acre site on the campus of the Texas A&M Health Science Center in Bryan, Texas. The custom-designed 145,000 square foot biotherapeutic production facility will be constructed and managed by G-Con. The company will integrate their proprietary modular, mobile, clean room "pods" in which the specialized purification and laboratory equipment will be located. These pods, as well as the flexible processes and facility design that led to the GreenVax project, were designed and developed for the National Center for Therapeutics Manufacturing (NCTM) - a State of Texas core biological pharmaceutical manufacturing, research and education facility now in construction on the Texas A&M University campus, under the management of the Texas Engineering Experiment Station (TEES) and supported by the Texas Emerging Technology Fund.

"Project GreenVax and the NCTM are game-changers. They have the potential to transform not just vaccine production, but the entire biopharmaceutical manufacturing industry," said Dr. Brett Giroir, vice chancellor for research for the A&M System and executive director of the Institute for Innovative Therapeutics (IIT), the newly established institute representing the partnership between the system's multiple state-of-the-art research facilities.

"Although the initial goal is to produce influenza vaccines," added Dr. Barry Holtz, president of G-Con, "plant-based production is highly adaptable to other infectious diseases and even cancer."


'/>"/>

Contact: Jason Cook
jason.cook@tamu.edu
979-845-2217
Texas A&M University
Source:Eurekalert

Related medicine news :

1. Texas-Based Regency Nursing and Rehabilitation Centers to Pay U.S. $4 Million to Resolve False Claims Act Allegations
2. Texas-Based Mobile Health Screening Company Expands into Dallas-Fort Worth
3. Regional Radiology Groups Form a National Consortium
4. MIT's Center for Transportation & Logistics Announces new Environmental Performance Consortium at Annual Crossroads Conference
5. The Security Consortium Announces Support for White House Cyber Chief Schmidt
6. University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources
7. University HealthSystem Consortium and ECRI Institute(R) to Provide Enhanced Health Technology Assessment Services
8. Turkey Genome Sequencing Consortium awarded $0.9 million from USDA
9. UT Southwestern receives continued NIH funding for Inner City Asthma Consortium
10. Pitt researcher to co-direct national consortium on facial birth defects
11. Metropolitan Chicago Breast Cancer Task Force Announced Members of Chicago Breast Cancer Quality Consortium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ChenMed , a leading provider of ... Senior Medical Center as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate ... Chief Medical Officer of Ambulatory Services for the UVA Health System, brings 30 years ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing homes, ... designed to accommodate patients with a wide range of ailments or special needs, but ... invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many uses, ...
(Date:7/20/2017)... ... 20, 2017 , ... Vixiar Medical, Inc. , a ... for monitoring cardiopulmonary diseases, announced today that it has raised seed round financing ... and fund final engineering and initial production of the Company’s first product, Indicor™, ...
(Date:7/20/2017)... Wisconsin (PRWEB) , ... July 20, 2017 , ... ... of two products that further expand its existing adherence automation lines. The ATP® ... that mirror the advanced technology of TCG’s standard products, but at a size ...
(Date:7/20/2017)... ... July 20, 2017 , ... A budget proposal to switch ... of - living - adjustment (COLA) is a bad deal for older and disabled ... price index (CPI) would grow even more slowly than the conventional one that is ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... , July 6, 2017 ThriveRx, the nutrition division of Diplomat ... families to thrive on nutrition support. To celebrate its anniversary, ... site has a fresh new look with improved organization to create the ... ... "We,ve ...
(Date:7/5/2017)... company of over 2,000 employees and a leader in environmental and life science ... their position as the top American owned and operated environmental testing firm in ... ... ... , enhances Pace Analytical,s capability as an innovative full service provider in ...
(Date:6/30/2017)... 2017 In vitro diagnostics market firm Kalorama ... at least ten diagnostic companies have successfully completed financings.  ... and a loan facility.  The size of these financings ... Kalorama Information provides a monthly IVD Market Trends ... Center. "Diagnostics ...
Breaking Medicine Technology: